Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.774 USD | -2.89% | -5.61% | -93.05% |
May. 13 | Investors Eye Key Inflation Data in Days Ahead as US Futures Trend Modestly Higher Monday | MT |
May. 13 | Top Premarket Gainers | MT |
Valuation
Fiscal Period: December | 2022 | 2023 |
---|---|---|
Capitalization 1 | - | - |
Enterprise Value (EV) 1 | - | - |
P/E ratio | -11.8 x | -4.56 x |
Yield | - | - |
Capitalization / Revenue | - | - |
EV / Revenue | - | - |
EV / EBITDA | - | - |
EV / FCF | - | - |
FCF Yield | - | - |
Price to Book | -7.53 x | -2.92 x |
Nbr of stocks (in thousands) | - | - |
Reference price 2 | 10.33 | 11.13 |
Announcement Date | 1/10/24 | 4/29/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Net sales | - | - | - |
EBITDA 1 | -4.609 | -13.63 | -8.68 |
EBIT 1 | -4.618 | -13.72 | -8.843 |
Operating Margin | - | - | - |
Earnings before Tax (EBT) 1 | -15.6 | -22.04 | -60.48 |
Net income 1 | -15.6 | -22.04 | -60.48 |
Net margin | - | - | - |
EPS 2 | -0.6219 | -0.8728 | -2.443 |
Free Cash Flow | - | -4.115 | -3.521 |
FCF margin | - | - | - |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 1/10/24 | 1/10/24 | 4/29/24 |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Net Debt 1 | 16.4 | 34.5 | 94.4 |
Net Cash position 1 | - | - | - |
Leverage (Debt/EBITDA) | -3.549 x | -2.532 x | -10.87 x |
Free Cash Flow | - | -4.11 | -3.52 |
ROE (net income / shareholders' equity) | - | 87.4% | 94.2% |
ROA (Net income/ Total Assets) | - | -111% | -83.5% |
Assets 1 | - | 19.78 | 72.46 |
Book Value Per Share 2 | -0.6600 | -1.370 | -3.820 |
Cash Flow per Share 2 | 0.2800 | 0.2200 | 0.0400 |
Capex 1 | 0.11 | 0.48 | 0.13 |
Capex / Sales | - | - | - |
Announcement Date | 1/10/24 | 1/10/24 | 4/29/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-93.05% | 131M | |
+52.36% | 56.69B | |
-3.86% | 41B | |
+38.14% | 38.11B | |
-12.01% | 26.89B | |
+14.13% | 25.59B | |
-21.62% | 18.59B | |
+0.21% | 12.39B | |
+25.96% | 11.99B | |
+23.02% | 11.88B |
- Stock Market
- Equities
- TVGN Stock
- Financials Tevogen Bio Holdings Inc.